Umd, Inc.
Records under this name other than patents Umd, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,527,614 | Protective Tube for a Medicated Tampon Formerly held Term ended Ended no later than Jan 30, 2026 · Medium confidence | Term ended | Ended no later than Jan 30, 2026 | Medium confidence |
| US 7,939,098 | Compositions and method for transmucosal drug delivery and cryoprotection Formerly held Lapsed on the fee record Ended May 10, 2019 · USPTO record | Lapsed on the fee record | Ended May 10, 2019 | USPTO record |
| US 6,086,909 | Device and method for treatment of dysmenorrhea Formerly held Term ended Term ended Feb 12, 2019 · USPTO record | Term ended | Term ended Feb 12, 2019 | USPTO record |
| US 7,744,916 | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs Formerly held Lapsed on the fee record Ended Jun 29, 2018 · USPTO record | Lapsed on the fee record | Ended Jun 29, 2018 | USPTO record |
| US 6,197,327 | Device and method for treatment of dysmenorrhea Formerly held Term ended Term ended May 15, 2018 · USPTO record | Term ended | Term ended May 15, 2018 | USPTO record |
| US 7,341,737 | Medicated Tampon Formerly held Term ended Term ended May 15, 2018 · Medium confidence | Term ended | Term ended May 15, 2018 | Medium confidence |
| US 6,982,091 | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy Formerly held Lapsed on the fee record Ended Jan 3, 2018 · USPTO record | Lapsed on the fee record | Ended Jan 3, 2018 | USPTO record |
| US 6,905,701 | Formulations for transmucosal vaginal delivery of bisphosphonates Formerly held Lapsed on the fee record Ended Jun 14, 2017 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2017 | USPTO record |
| US 8,178,123 | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration Formerly held Lapsed on the fee record Ended May 15, 2016 · USPTO record | Lapsed on the fee record | Ended May 15, 2016 | USPTO record |
| US 6,572,874 | Vaginal delivery of bisphosphonates Formerly held Lapsed on the fee record Ended Jun 3, 2015 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2015 | USPTO record |